Health · 1 sources covering this

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: Merck suffers a setback in Europe over its new Keytruda formulation
In a setback for Merck, a Dutch court ordered a halt to the manufacturing and marketing of a subcutaneous formulation of Keytruda in several European countries.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/52684510c63d20d9a63ce02e86bb2b176d006e2e"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Merck suffers a setback in Europe over its new Keytruda formulation"></iframe>

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

How 1 sources are covering this

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

More from Health

Gut microbes followed migrating humans across continents, new study suggests

STAT+: Forbion raises $2.6 billion, its largest fundraise to date

STAT+: Why health AI pilots in Utah may be on a collision course with the FDA

DIY fertilizer is a blessing as farmers face steep prices due to the Iran war

Reader

Trust & legal

Across the network